SCHEMBL2670237

SCHEMBL2670237

COc1[c]ccc2c(=O)c(C(=O)O)cn([C@@H]3C[C@@H]3F)c12

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 1/20 0.52
KCNH2 Q12809 5/20 0.39
KDM4E B2RXH2 5/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
CYP1A2 P05177 1/20 0.36
GSK3B P49841 1/20 0.35
TOP2A P11388 2/20 0.35
TOP2B Q02880 2/20 0.35
ALDH1A1 P00352 2/20 0.35
HPGD P15428 2/20 0.35
HSD17B10 Q99714 2/20 0.35
POLB P06746 1/20 0.35
PRKD3 O94806 1/20 0.35
ALOX15 P16050 1/20 0.35
OPRM1 P35372 1/20 0.35
CLK2 P49760 1/20 0.35
CLK4 Q9HAZ1 1/20 0.35
TDP1 Q9NUW8 1/20 0.35
TSHR P16473 1/20 0.34
RAB9A P51151 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5619575 1.00 CYP3A4 (0.52) CYP3A4KCNH2KDM4ESMN1; SMN2CYP1A2
SCHEMBL5619151 0.87 CYP3A4 (0.45) CYP3A4KCNH2KDM4ESMN1; SMN2CYP1A2
SCHEMBL2670500 0.87 CYP3A4 (0.45) CYP3A4KCNH2KDM4ESMN1; SMN2CYP1A2
SCHEMBL2670396 0.85 KCNH2 (0.52) KCNH2KDM4EGSK3BTOP2ATOP2B
SCHEMBL2670512 0.85 CYP3A4 (0.48) CYP3A4KCNH2KDM4ESMN1; SMN2CYP1A2
SCHEMBL2670716 0.83 CYP3A4 (0.46) CYP3A4KCNH2KDM4ESMN1; SMN2CYP1A2
SCHEMBL2670677 0.81 CYP3A4 (0.45) CYP3A4KCNH2KDM4ESMN1; SMN2CYP1A2
SCHEMBL5235241 0.81 CYP3A4 (0.45) CYP3A4KCNH2KDM4ESMN1; SMN2CYP1A2
SCHEMBL2670607 0.80 CYP3A4 (0.44) CYP3A4KCNH2KDM4ESMN1; SMN2CYP1A2
SCHEMBL4714888 0.80 CYP3A4 (0.52) CYP3A4KDM4ESMN1; SMN2CYP1A2GSK3B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130029977-A9 Fused substituted aminopyrrolidine derivative DAIICHI SANKYO COMPANY, LIMITED 2013-01-31 US claimed
US-20120108582-A1 Fused substituted aminopyrrolidine derivative DAIICHI SANKYO COMPANY, LIMITED 2012-05-03 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120108582-A1 Fused substituted aminopyrrolidine derivative NQO2, QDPR, IL4I1 CYP3A4 153/4885KCNH2 193/4885KDM4E 1244/4885
US-20130029977-A9 Fused substituted aminopyrrolidine derivative NQO2, QDPR, IL4I1 CYP3A4 153/4885KCNH2 193/4885KDM4E 1244/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.